New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
19:16 EDTWTW, GSK, ARNA, PHMD, LCAV, CRAY, LOGM, CLF, Z, VSI, A, TRLA, GNC, NNAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cliffs Natural (CLF), up 6.4% after reporting better-than-expected earnings and announcing it promoted Gary Halverson, formerly its president and COO, to president and CEO... LogMeln (LOGM), up 16%... Cray (CRAY), up 9.7%. ALSO HIGHER: LCA Vision (LCAV), up 29% after announcing an agreement to be acquired by PhotoMedex (PHMD) for $5.37 per share. Shares of PhotoMedex were little changed following the announcement... Arena Pharmaceuticals (ARNA), up 1.8% after the Daily Mail said GlaxoSmithKline (GSK) could be interested in a deal for the company. DOWN AFTER EARNINGS: Weight Watchers (WTW), down 20% after fourth quarter profit missed expectations and the company sharply cut its fiscal 2014 earnings outlook... GNC Holdings (GNC), down 15.7%... Trulia (TRLA), down 15.2%... Agilent (A), down 6%. ALSO LOWER: Vitamin Shoppe (VSI), down 8.5% after its vitamin retailing peer GNC reported disappointing fourth quarter sales and cut its fiscal 2014 outlook... Zillow (Z), down 3% after online real estate peer Trulia's quarterly report disappointed... Navios Maritime Acquisition (NNA), down 8.4% after filing to sell 12M shares of common stock.
Check below for free stories on WTW;GNC;TRLA;A;VSI;Z;CLF;LOGM;CRAY;LCAV;PHMD;ARNA;GSK;NNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 10, 2014
12:23 EDTCLFCasblanca Capital condemns Cliffs Natural's compensation practices in letter
Casablanca Capital LP, the beneficial owner of approximately 5.2% of Cliffs Natural Resources, issued a letter to shareholders in connection with Casablanca’s campaign for fundamental change at Cliffs and its nomination of six director candidates for election to the Board of Directors at the company’s upcoming 2014 Annual Meeting of Shareholders on July 29. In the letter, Casablanca details escalating management compensation while shareholder returns have plummeted, the opaque nature of the management bonus and review process, and the ways in which bonus compensation metrics have changed from year to year in an apparent effort by the Cliffs Board to justify management bonuses despite severe underperformance. Casablanca reiterates that, in contrast to the current 0.3% of Cliffs shares that the current Board and management team owns, Casablanca has economically aligned itself with the interests of fellow shareholders, with Casablanca owning 5.2% of Cliffs shares and with Lourenco Goncalves’ personal investment of $1.5M in Cliffs’ shares. Donald Drapkin, Chairman of Casablanca said, “The Cliffs Board and management team have been pursuing their own personal agendas and enrichment at the expense of shareholders for far too long. It is time for the gravy train to end and for the Board to be held accountable. We are confident that on July 29 Cliffs’ shareholders will vote to support a slate of new directors who will reverse the outrageous value destruction and stop the pattern of excessive compensation and self-dealing at Cliffs.”
12:21 EDTCRAYOn The Fly: Midday Wrap
Subscribe for More Information
11:13 EDTCRAYCray rallies sharply, levels to watch
Subscribe for More Information
11:09 EDTGNCOptions with increasing implied volatility
Subscribe for More Information
09:04 EDTCRAYCray awarded $174M supercomputer contract from NNSA
Subscribe for More Information
08:35 EDTCLFBofA/Merrill steel analysts hold an analyst/industry conference call
Global Steel Analysts review market conditions in Asia, Europe and the U.S. and discuss recent price moves in iron ore, met coal and global steel on an Analyst/Industry conference call. Covered companies AKS, ATI, CLF, CMC, GGB, MTL, NUE, RS, SCHN, SID, STLD, TX and X may be discussed on the Analyst/Industry conference call to be held on July 14 at 10 am.
08:08 EDTARNAArena Pharmaceuticals reports that Eisai increases sales force for Belviq
Arena Pharmaceuticals reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for Belviq by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the U.S.
July 9, 2014
12:25 EDTGNCGNC Holdings calls active as shares move off 17-month low
Subscribe for More Information
11:51 EDTLOGMLogMeln weakness after short report a buying opportunity, says Piper Jaffray
Piper Jaffray attributes today's weakness in shares of LogMeIn to a short report out on the company, but the firm disagrees with the report, which it thinks understates the strength of LogMeIn's core business and opportunities. Piper reiterates its Overweight rating and $56 price target on LogMeIn.
11:51 EDTGNCOptions with increasing implied volatility:
Subscribe for More Information
11:24 EDTGNCHigh option volume stocks
10:37 EDTLOGMLogMeln responds to 'short thesis' report from Off Wall Street
Subscribe for More Information
10:02 EDTLOGM, Z, TRLA, NNAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:20 EDTLOGMLogMeln initited with a Sell at Off Wall Street
Subscribe for More Information
06:47 EDTGSKGlaxoSmithKline, Theravance announces Australia approval of Anoro Ellipta
Subscribe for More Information
July 8, 2014
18:21 EDTNNANavios Acquisition initiated with a Hold at Canaccord
Subscribe for More Information
18:19 EDTTRLATrulia initiated with an Outperform at Macquarie
Target $56.
18:19 EDTZZillow initiated with an Outperform at Macquarie
Subscribe for More Information
07:09 EDTZZillow reports 82.99M monthly unique users in June
Subscribe for More Information
06:39 EDTGSKChina aims to handle GSK trial 'according to law,' Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use